Legend Biotech (LEGN) Sets Up ASH Pipeline Data, Is The Stock Still A Bargain?

Legend Biotech (NasdaqGS:LEGN) is back in focus after revealing a slate of new data on its CARVYKTI therapy and next generation cell therapy candidates that are scheduled for presentation at the 2026 ASH Annual Meeting.

Legend Biotech’s latest ASH update lands after a sharp 21.63% 30 day share price return and a 9.73% gain over 90 days, even though the 1 year total shareholder return is down 29.66%. This suggests short term momentum has improved while longer term holders remain underwater.

Scan beyond Legend Biotech and compare its ASH-fueled momentum with 38 healthcare AI stocks, which are also pushing the frontier in hematology and oncology.

Bulls see Legend Biotech’s ASH pipeline spotlight and recent rebound as a sign the market is waking up. Bears point to the long slide and ongoing losses. Which story does the current valuation lean toward?

Most Popular Narrative: 51% Undervalued

Legend Biotech’s most followed valuation narrative pegs fair value at $46.81, more than double the last close at $22.77. This frames the latest ASH buzz as part of a bigger long term story rather than a short term squeeze.

Robust innovation pipeline, including next-generation CAR-Ts and in vivo/off-the-shelf cell therapy technologies (e.g., TaVec platform), positions Legend to capitalize on rising demand for advanced, personalized therapies amid secular increases in cancer incidence and sustained healthcare investment, supporting future revenue streams and risk diversification.

See why 26 investors see Legend Biotech as 51% undervalued.

Result: Fair Value of $46.81 (UNDERVALUED)

Still, the Legend Biotech narrative could be knocked off course if competition squeezes CARVYKTI’s opportunity or if heavy R&D and partnership costs keep profitability distant.

Find out about the key risks to this Legend Biotech narrative.

Next Steps

If the Legend Biotech story so far feels split between optimism and caution, use that tension as a cue to act now and test the numbers yourself. Start by weighing the potential upside flagged in the 4 key rewards.

Looking for more Legend Biotech sized ideas?

Legend Biotech might be front of mind today, but your next strong idea could be sitting in plain sight if you cast the net a little wider.

• Target potential mispricing by scanning a curated pool of companies that combine quality fundamentals with appealing valuations through the 35 high quality undervalued stocks.
• Build a sturdier core for your portfolio by focusing on businesses with cleaner finances and resilient capital structures using the list of solid balance sheet and fundamentals (24 results).
• Get ahead of the crowd by tracking a focused set of underfollowed opportunities with strong fundamentals through the 19 high quality undiscovered gems.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com